FDA warned P.T. Sankei Medical Industries over unapproved changes to its single-use sphygmomanometer and quality system violations.
What happened
FDA inspected the Banten, Indonesia facility May 8–11, 2023. The investigator found the firm had changed materials for its cleared sphygmomanometer without a new 510(k), and found quality system and medical device reporting procedure violations. FDA said the May 24, 2023 response was not adequate.
What FDA found
The firm changed the materials of its cleared sphygmomanometer without submitting a new 510(k), which FDA said could affect safety or effectiveness.
21 CFR 807.81(a)(3)(i)The firm did not apply design controls to the single-use sphygmomanometer.
21 CFR 820.30(a)The firm's purchasing procedure did not define supplier quality requirements or require supplier agreements to notify it of changes.
21 CFR 820.50Device history records did not include the primary label and labeling location and did not require technicians to document manufacturing steps.
21 CFR 820.184The complaint procedure did not require review and evaluation of all complaints, records of no-investigation decisions, or evaluation for MDR reporting.
21 CFR 820.198The MDR procedure lacked definitions, a standardized review process, instructions for timely report submission, and recordkeeping requirements.
21 CFR 803.17
What FDA wants
FDA tells the firm to respond in writing within 15 business days with the specific corrections and corrective actions, including evidence and English translations, and to explain how it will prevent recurrence.
Who should pay attention
- distributors and importers of Sankei sphygmomanometers
- US agent and buyers of single-use blood pressure cuffs
- QA teams at device firms with supplier changes
This is a summary. Read the original letter on fda.gov.